



2

Financial Statements

Quarter Ended
June 30, 2025

5N+

INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of United States dollars) (unaudited)

	Notes	June 30 2025	December 31 2024
		\$	\$
Assets			
Current			
Cash		48,624	22,142
Accounts receivable		58,485	42,172
Inventories	3	142,960	137,823
Income tax receivable		850	1,811
Derivative financial assets	10	3,131	6,978
Other current assets		5,895	6,469
Total current assets		259,945	217,395
Property, plant and equipment	6	93,584	85,995
Right-of-use assets	6	29,373	28,583
Intangible assets	6	24,213	22,929
Goodwill		12,032	10,665
Deferred tax assets		9,439	7,358
Other assets	10	3,350	3,982
Total non-current assets		171,991	159,512
Total assets		431,936	376,907
Liabilities			
Current			
Trade and accrued liabilities		50,916	42,116
Income tax payable		10,733	5,207
Current portion of deferred revenue	4	13,834	11,206
Current portion of lease liabilities		2,115	1,952
Total current liabilities		77,598	60,481
Long-term debt	5	122,961	122,203
Deferred tax liabilities		6,216	5,737
Employee benefit plan obligations		13,272	12,624
Lease liabilities		28,856	27,450
Deferred revenue	4	10,103	8,688
Other liabilities		797	706
Total non-current liabilities		182,205	177,408
Total liabilities		259,803	237,889
Equity		172,133	139,018
Total liabilities and equity		431,936	376,907

Commitments and contingencies (Note 11)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5N PLUS INC.**INTERIM CONSOLIDATED STATEMENTS OF EARNINGS**

For the three and six-month periods ended June 30

(in thousands of United States dollars, except per share information) (unaudited)

	Notes	Three months		Six months	
		2025	2024	2025	2024
		\$	\$	\$	\$
Revenue		95,311	74,580	184,199	139,599
Cost of sales	3, 6	65,888	54,385	127,780	102,405
Selling, general and administrative expenses	6	7,699	8,717	16,259	16,034
Other expenses (income), net	6	2,251	2,329	5,576	4,579
		75,838	65,431	149,615	123,018
Operating earnings		19,473	9,149	34,584	16,581
Financial expense					
Interest on long-term debt		2,002	2,146	4,006	3,941
Imputed interest and other interest expense		351	(272)	1,064	139
Foreign exchange (gain) loss		(97)	2	(811)	(385)
		2,256	1,876	4,259	3,695
Earnings before income taxes		17,217	7,273	30,325	12,886
Income tax expense (recovery)					
Current		4,706	2,177	8,077	4,691
Deferred		(2,716)	307	(2,552)	899
		1,990	2,484	5,525	5,590
Net earnings		15,227	4,789	24,800	7,296
Basic earnings per share	7	0.17	0.05	0.28	0.08
Diluted earnings per share	7	0.17	0.05	0.28	0.08

Net earnings are completely attributable to equity holders of 5N Plus Inc.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5N PLUS INC.**INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

For the three and six-month periods ended June 30

(in thousands of United States dollars) (unaudited)

	Three months		Six months	
	2025	2024	2025	2024
	\$	\$	\$	\$
Net earnings	15,227	4,789	24,800	7,296
Other comprehensive income (loss)				
Items that may be reclassified subsequently to net earnings				
Currency translation adjustment	5,287	(373)	7,674	(1,414)
	5,287	(373)	7,674	(1,414)
Items that will not be reclassified subsequently to net earnings				
Remeasurement of employee benefit plan obligations	102	300	733	488
Income taxes	(32)	(93)	(230)	(151)
	70	207	503	337
Other comprehensive income (loss)	5,357	(166)	8,177	(1,077)
Comprehensive income	20,584	4,623	32,977	6,219

Comprehensive income is completely attributable to equity holders of 5N Plus Inc.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5N PLUS INC.**INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

For the six-month periods ended June 30

(in thousands of United States dollars, except number of shares) (unaudited)

	Number of shares	Share Capital	Contributed Surplus	Accumulated other comprehensive loss	Deficit	Total equity
2025						
Balances at beginning of period	89,042,801	\$ 22,795	\$ 342,982	\$ (11,604)	\$ (215,155)	\$ 139,018
Net earnings for the period	-	-	-	-	24,800	24,800
Other comprehensive income	-	-	-	8,177	-	8,177
Comprehensive income	-	-	-	8,177	24,800	32,977
Exercise of stock options	25,000	60	(17)	-	-	43
Share-based compensation	-	-	95	-	-	95
Balances at end of period	89,067,801	22,855	343,060	(3,427)	(190,355)	172,133

	Number of shares	Share Capital	Contributed Surplus	Accumulated other comprehensive loss	Deficit	Total equity
2024						
Balances at beginning of period	88,704,724	\$ 21,884	\$ 343,012	\$ (6,477)	\$ (229,827)	\$ 128,592
Net earnings for the period	-	-	-	-	7,296	7,296
Other comprehensive loss	-	-	-	(1,077)	-	(1,077)
Comprehensive (loss) income	-	-	-	(1,077)	7,296	6,219
Exercise of stock options	213,077	601	(172)	-	-	429
Share-based compensation	-	-	116	-	-	116
Balances at end of period	88,917,801	22,485	342,956	(7,554)	(222,531)	135,356

Equity is completely attributable to equity holders of 5N Plus Inc.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5N PLUS INC.**INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**

For the six-month periods ended June 30

(in thousands of United States dollars) (unaudited)

	Notes	2025	2024
		\$	\$
Operating activities			
Net earnings		24,800	7,296
Adjustments to reconcile net earnings to cash flows			
Depreciation of property, plant and equipment		5,742	5,056
Depreciation of right-of-use assets		1,317	1,293
Amortization of intangible assets		1,393	1,645
Amortization of other assets		361	124
Loss on remeasurement of financial instrument	6, 10	1,000	-
Impairment of non-current assets	6	-	307
Share-based compensation expense		3,376	4,777
Deferred income taxes		(2,552)	899
Imputed interest		636	602
Employee benefit plan obligations		(209)	(93)
Loss on disposal of property, plant and equipment		16	27
Unrealized gain on non-hedge financial instruments		(3,053)	(4,673)
Unrealized foreign exchange loss (gain) on assets and liabilities		1,817	(613)
Cash from operations before the following:		34,644	16,647
Net change in non-cash working capital balances	9	(5,990)	(19,265)
Cash from (used in) operating activities		28,654	(2,618)
Investing activities			
Additions to property, plant and equipment	9	(8,098)	(14,277)
Additions to intangible assets		(344)	(160)
Acquisition of investment in equity instruments	10	-	(1,000)
Proceeds on settlement of total return swap	10	6,898	-
Proceeds on disposal of property, plant and equipment		-	961
Cash from (used in) investing activities		(1,544)	(14,476)
Financing activities			
Repayment of long-term debt		-	(10,000)
Proceeds from issuance of long-term debt		876	20,889
Deferred costs related to long-term debt		(737)	(100)
Issuance of common shares		43	429
Principal elements of lease payments		(1,552)	(1,512)
Cash flows (used in) from financing activities		(1,370)	9,706
Effect of foreign exchange rate changes on cash		742	(173)
Net increase (decrease) in cash		26,482	(7,561)
Cash at beginning of period		22,142	34,706
Cash at end of period		48,624	27,145
Supplemental information⁽¹⁾			
Income tax paid		1,677	3,429
Interest paid		3,371	3,573

⁽¹⁾ Amounts paid for income tax and interest were reflected as cash flows from operating activities in the interim consolidated statements of cash flows.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. Nature of Activities

5N Plus Inc. ("5N+" or the "Company") is a Canadian-based international company. 5N+ is a global producer of specialty semiconductors and performance materials. The Company's ultra-pure materials often form the core element of its customer products. These customers rely on 5N+'s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company's products enable various applications in a number of key industries including renewable energy, security, space, pharmaceutical, medical imaging and industrial. The Company is headquartered at 4385 Garand Street, Montreal, Quebec (Canada) H4R 2B4. The Company operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia. The Company's mission is to be critical to its customers, valued by its employees and trusted by its shareholders. The Company's core values focus on integrity, commitment and customer development along with emphasis on sustainable development, continuous improvement, health and safety. The Company's shares are listed on the Toronto Stock Exchange ("TSX"). 5N+ and its subsidiaries represent the "Company" mentioned throughout these consolidated financial statements. The Company has two reportable business segments, namely Specialty Semiconductors and Performance Materials.

These condensed interim consolidated financial statements were approved by the Board of Directors on August 4, 2025.

2. Basis of Presentation

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS Accounting Standards") and as applicable to the preparation of interim financial statements, including IAS 34, "Interim Financial Reporting". These condensed interim consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2024, which have been prepared in accordance with IFRS Accounting Standards.

The preparation of financial statements in accordance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The accounting policies followed in these unaudited condensed interim financial statements are consistent with those of the previous financial year, with the additional policy described below.

The functional and presentation currency of the Company is the United States dollar.

Income taxes

Taxes on income in interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

3. Inventories

	June 30 2025	December 31 2024
	\$	\$
Raw materials	57,712	51,316
Finished goods	85,248	86,507
Total inventories	142,960	137,823

For the three and six-month periods ended June 30, 2025, a total of \$43,854 and \$80,417 of inventories were included as an expense in cost of sales (\$29,391 and \$58,785 for the three and six-month periods ended June 30, 2024).

4. Deferred revenue

	June 30 2025	December 31 2024
	\$	\$
Prepayments from clients	12,200	9,754
Current portion of deferred revenue related to long-term contracts	1,634	1,452
Current portion of deferred revenue	13,834	11,206
Non-current portion of deferred revenue related to long-term contracts	10,103	8,688
Non-current portion of deferred revenue	10,103	8,688
Total deferred revenue	23,937	19,894

For the six-month period ended June 30, 2025, \$5,375 (2024 - \$8,403) of revenue was realized in relation to the deferred revenue balance outstanding at the beginning of the period.

5. Long-Term Debt

	June 30 2025	December 31 2024
	\$	\$
Senior secured revolving facility of \$154,000 with a syndicate of banks, maturing in March 2029	105,500	105,500
Subordinated term loan with Investissement Québec, maturing in March 2028	15,000	15,000
Interest-free loan from Investissement Québec, maturing in February 2030	1,339	1,210
Interest-free loan from Canada Economic Development for Quebec Regions, maturing in December 2032	1,122	493
	122,961	122,203
Less current portion of long-term debt	-	-
	122,961	122,203

Senior secured revolving facility

In March 2025, the Company signed a senior secured multi-currency revolving credit facility of \$154,000 maturing in March 2029 to replace its existing \$124,000 senior secured revolving facility maturing in April 2026. At any time, the Company has the option to request that the credit facility be expanded through the exercise of an additional \$50,000 accordion feature, subject to review and approval by the lenders. This revolving credit facility can be drawn in US dollars, Canadian dollars or Hong Kong dollars (up to \$4,000). Drawings bear interest at either the Canadian prime rate, US base rate, Hong Kong base rate, SOFR or CORRA, plus a margin based on the Company's senior net debt to consolidated EBITDA ratio. Under the terms of its credit facility, the Company is required to satisfy certain restrictive covenants as to financial ratios. As at June 30, 2025 and December 31, 2024, the Company had met all covenants.

Subordinated term loan from Investissement Québec

In March 2024, the Company entered into a subordinated term loan agreement with Investissement Québec of \$15,000 which replaces its previous subordinated term loan of \$25,000 set to expire in March 2024. The new term loan bears interest equivalent to the four-year US Treasury Bonds plus a margin of 5.38%, which equals to 9.71%. Under the terms of the loan, the Company is required to satisfy certain restrictive covenants as to financial ratios. As at June 30, 2025 and December 31, 2024, the Company has met all covenants.

Interest-free loan from Investissement Québec

In February 2024, the Company received CA\$ 2,700 from Investissement Québec with respect to an interest-free term loan with a maximum drawdown of CA\$ 2,850 dependent upon eligible capital expenditures related to investments in its Montreal production facility. Subject to the satisfaction of certain criteria, the Company expects CA\$ 500 of the loan to be forgiven. The loan has a two-year repayment moratorium period and is subsequently reimbursable in monthly instalments over a period of four years. Under the terms of the loan, the Company is required to satisfy certain restrictive covenants as to financial ratios. As at June 30, 2025 and December 31, 2024, the Company has met all covenants.

Interest-free loan from Canada Economic Development for Quebec Regions

In March 2025, the Company received CA\$ 1,258 from Canada Economic Development for Quebec Regions with respect to an interest-free term loan with a maximum drawdown of CA\$ 3,000 dependent upon eligible capital expenditures, bringing the Company's total drawdown to CA\$ 2,475. At a date no later than December 31, 2025, an additional two-year repayment moratorium period will begin. Subsequently, the loan is reimbursable in monthly instalments over a period of five years.

6. Expenses by Nature

	Three months		Six months	
	2025	2024	2025	2024
	\$	\$	\$	\$
Wages and salaries	15,955	16,053	31,444	30,393
Depreciation of property, plant and equipment	2,935	2,571	5,742	5,056
Depreciation of right-of-use assets	670	656	1,317	1,293
Amortization of other assets	37	61	361	124
Other expenses (income), net				
Amortization of intangible assets	719	822	1,393	1,645
Share-based compensation expense	(807)	(15)	586	345
Loss on disposal of property, plant and equipment	9	25	16	27
Loss on remeasurement of financial instrument (Note 10)	1,000	-	1,000	-
Impairment of non-current assets ⁽¹⁾	-	307	-	307
Research and development, net of tax credit ⁽²⁾	1,191	1,213	2,300	2,297
ERP Implementation costs ⁽³⁾	156	-	316	-
Other income	(17)	(23)	(35)	(42)

⁽¹⁾ During the second quarter of 2024, the Company recorded an impairment of non-current assets of \$307 in relation to Property, plant and equipment included within the Specialty Semiconductors segment, to reflect the assessment of the carrying value of production equipment following the Company's decision to discontinue construction of the asset.

⁽²⁾ Research and development, net of tax credit was reduced by an amount of \$385 and \$778 for the three and six-month periods ended June 30, 2025 resulting from research and development subsidies. There is an outstanding receivable related to this grant as at June 30, 2025 for an amount of \$2,359 included within Accounts receivable.

Research and development, net of tax credit was reduced by an amount of \$338 and \$698 for the three and six-months period ended June 30, 2024 resulting from research and development subsidies.

⁽³⁾ ERP implementation costs of \$156 and \$316 were incurred in relation to its Montreal site for the three-month and six-month periods ended June 30, 2025.

7. Earnings per Share

The following table reconciles the numerators and denominators used for the computation of basic and diluted net earnings per share:

Numerators	Three months		Six months	
	2025	2024	2025	2024
	\$	\$	\$	\$
Net earnings for the period	15,227	4,789	24,800	7,296
Denominators	Three months		Six months	
	2025	2024	2025	2024
Basic weighted average number of shares	89,056,263	88,818,002	89,049,569	88,775,869
Dilutive effect:				
Stock options	822,119	785,003	810,211	739,298
Diluted weighted average number of shares	89,878,382	89,603,005	89,859,780	89,515,167

For the three and six-month periods ended June 30, 2025, 68,219 stock options were excluded from the diluted weighted average number of shares due to their anti-dilutive effect.

For the three and six-month periods ended June 30, 2024, 139,620 stock options were excluded from the diluted weighted average number of shares due to their anti-dilutive effect.

8. Operating Segments

The following tables summarize the information reviewed by the entity's chief operating decision maker when measuring performance:

	Three months		Six months	
	2025	2024	2025	2024
	\$	\$	\$	\$
Specialty Semiconductors	71,213	52,340	134,017	97,490
Performance Materials	24,098	22,240	50,182	42,109
Total revenue	95,311	74,580	184,199	139,599
Specialty Semiconductors	18,985	13,072	36,675	22,629
Performance Materials	8,027	3,859	14,105	8,771
Corporate and unallocated	(2,866)	(3,441)	(5,842)	(6,173)
Adjusted EBITDA ⁽¹⁾	24,146	13,490	44,938	25,227
Interest on long-term debt, imputed interest and other interest expense	2,353	1,874	5,070	4,080
Share-based compensation (recovery) expense	(807)	(15)	586	345
Foreign exchange gain	(97)	2	(811)	(385)
Depreciation and amortization	4,324	4,049	8,452	7,994
Loss on remeasurement of financial instrument (Note 6 and Note 10)	1,000	-	1,000	-
Impairment of non-current assets (Note 6)	-	307	-	307
ERP implementation costs (Note 6)	156	-	316	-
Earnings before income tax	17,217	7,273	30,325	12,886

⁽¹⁾ Earnings before income tax, depreciation and amortization, share-based compensation expense (recovery), ERP implementation costs, impairment of non-current assets and financial expense (income).

	Three months		Six months	
	2025	2024	2025	2024
Capital expenditures	\$	\$	\$	\$
Specialty Semiconductors	1,271	4,507	2,880	12,374
Performance Materials	499	807	3,285	1,856
Corporate and unallocated	1,933	7	1,933	47
Total	3,703	5,321	8,098	14,277

	June 30 2025	December 31 2024
Assets excluding deferred tax assets	\$	\$
Specialty Semiconductors	243,306	199,224
Performance Materials	150,645	146,788
Corporate and unallocated	28,546	23,537
Total	422,497	369,549

The geographic distribution of the Company's revenue based on the location of the customers for the three and six-month periods ended June 30, 2025 and 2024, and the identifiable non-current assets as at June 30, 2025 and December 31, 2024 are summarized as follows:

Revenues	Three months		Six months	
	2025	2024	2025	2024
	\$	\$	\$	\$
Asia				
China	3,802	3,376	6,829	5,913
Japan	1,859	1,190	3,837	2,502
Other ⁽¹⁾	13,368	3,205	18,478	8,535
Americas				
United States	40,988	36,527	88,144	66,968
Other	3,608	2,053	6,797	3,927
Europe				
Germany	16,638	16,038	32,008	27,269
Belgium	1,301	1,715	3,468	3,334
France	689	327	2,206	759
Other ⁽¹⁾	12,108	7,474	20,361	16,025
Other	950	2,675	2,071	4,367
Total	95,311	74,580	184,199	139,599

⁽¹⁾ None exceeding 10%

Non-current assets (other than deferred tax assets and financial instruments)	June 30 2025	December 31 2024
	\$	\$
Asia	2,878	3,007
United States	10,272	11,090
Canada	32,777	29,556
Germany	114,049	104,994
Total	159,976	148,647

For the three and six-month periods ended June 30, 2025, one customer represented approximately 33% and 32% (2024 – 27%) of revenues, all of which is within the Specialty Semiconductors segment.

9. Supplemental Cash Flow Information

Net change in non-cash working capital balances related to operations consists of the following:

	Six months	
	2025	2024
	\$	\$
(Increase) decrease in assets:		
Accounts receivable	(14,072)	(7,880)
Inventories	(71)	(11,019)
Income tax receivable	961	81
Other current assets	725	770
Increase (decrease) in liabilities:		
Trade and accrued liabilities	46	(2,941)
Income tax payable	5,262	924
Deferred revenue	1,159	800
Net change	(5,990)	(19,265)

The interim consolidated statements of cash flows exclude or include the following transactions:

	Six months	
	2025	2024
Excluded additions unpaid at end of the period:		
Additions to property, plant and equipment	\$ 539	\$ 847
Included additions unpaid at beginning of the period:		
Additions to property, plant and equipment	344	1,214
Excluded non-cash proceeds on the disposal of		
Property, plant and equipment	-	200

Additions to property, plant and equipment consist of the following:

	Six months	
	2025	2024
Additions to property, plant and equipment before prepayments	\$ 8,098	\$ 13,733
Prepayments for construction in progress	-	544
Additions to property, plant and equipment	8,098	14,277

As at June 30, 2025, property, plant and equipment includes \$225 of prepayments for construction in progress (\$669 as at December 31, 2024).

For the six-month period ended June 30, 2025, additions to property, plant and equipment included government assistance of \$345 (\$1,332 for the six-month period ended June 30, 2024) recognized in relation to interest-free loans (Note 5).

10. Fair Value of Financial Instruments

Fair value hierarchy

The following table presents the financial instruments, by level, which are recognized at fair value in the interim consolidated statements of financial position:

As at June 30, 2025	Level 1	Level 2	Level 3
	\$	\$	\$
Financial assets			
At fair value through profit or loss			
Total return swap ⁽¹⁾	-	3,131	-
Investment in equity instruments ⁽²⁾	-	-	2,000
Restricted investment ⁽³⁾	-	-	576
Total	-	3,131	2,576

As at December 31, 2024	Level 1	Level 2	Level 3
	\$	\$	\$
Financial assets			
At fair value through profit or loss			
Total return swap ⁽¹⁾	-	6,978	-
Investment in equity instruments ⁽²⁾	-	-	3,000
Restricted investment ⁽³⁾	-	-	507
Total	-	6,978	3,507

⁽¹⁾ In February 2025, the Company received \$6,898 upon the settlement and renewal of its Total return swap.

The Company utilizes the total return swap to reduce its income exposure to fluctuations in its share price relating to the DSU, PSU, RSU and SAR programs. Pursuant to the agreement, the Company receives the economic benefit of the share price appreciation while providing payments to the financial institution for the institution's cost of funds and any share price depreciation. The net effect of the total return swap partly offset movements in the Company's share price impacting the cost of the DSU, PSU, RSU and SAR programs. As at June 30, 2025, the total return swap covered 2,571,569 common shares of the Company.

⁽²⁾ In June 2025, a remeasurement loss on financial assets was recorded for \$1,000 based on the revised estimates of the fair value of the Company's equity instrument in Microbion to reflect the increased difficulties for pharmaceutical research companies to raise capital. As at June 30, 2025, the Company's stake in Microbion Corporation (Microbion), recorded in Other assets, was valued at \$2,000 (\$3,000 as at December 31, 2024).

⁽³⁾ The fair value of the restricted investment is recorded in Other assets.

11. Commitments and Contingencies

Commitments

In the normal course of business, the Company contracted letters of credit for an amount of up to \$261 as at June 30, 2025 (\$190 as at December 31, 2024).

Contingencies

In the normal course of operations, the Company is exposed to events that could give rise to contingent liabilities or assets. As at the date of issue of the condensed interim consolidated financial statements, the Company was not aware of any significant events that would have a material effect on its consolidated financial statements.